BACKGROUND:Caloric restriction (CR), energy intake reduced below ad libitum (AL) intake, increases life span in many species. The implications for humans can be clarified by randomized controlled trials of CR. METHODS: To determine CR's feasibility, safety, and effects on predictors of longevity, disease risk factors, and quality of life in nonobese humans aged 21-51 years, 218 persons were randomized to a 2-year intervention designed to achieve 25% CR or to AL diet. Outcomes were change from baseline resting metabolic rate adjusted for weight change ("RMR residual") and core temperature (primary); plasma triiodothyronine (T3) and tumor necrosis factor-α (secondary); and exploratory physiological and psychological measures. RESULTS:Body mass index averaged 25.1 (range: 21.9-28.0 kg/m(2)). Eighty-two percent of CR and 95% of AL participants completed the protocol. The CR group achieved 11.7±0.7 %CR (mean ± standard error) and maintained 10.4±0.4% weight loss. Weight change in AL was negligible. RMR residual decreased significantly more in CR than AL at 12 months (p = .04) but not 24 months (M24). Core temperature change differed little between groups. T3 decreased more in CR at M12 and M24 (p < .001), while tumor necrosis factor-α decreased significantly more only at M24 (p = .02). CR had larger decreases in cardiometabolic risk factors and in daily energy expenditure adjusted for weight change, without adverse effects on quality of life. CONCLUSIONS: Sustained CR is feasible in nonobese humans. The effects of the achieved CR on correlates of human survival and disease risk factors suggest potential benefits for aging-related outcomes that could be elucidated by further human studies. Published by Oxford University Press on behalf of the Gerontological Society of America 2015.
RCT Entities:
BACKGROUND: Caloric restriction (CR), energy intake reduced below ad libitum (AL) intake, increases life span in many species. The implications for humans can be clarified by randomized controlled trials of CR. METHODS: To determine CR's feasibility, safety, and effects on predictors of longevity, disease risk factors, and quality of life in nonobese humans aged 21-51 years, 218 persons were randomized to a 2-year intervention designed to achieve 25% CR or to AL diet. Outcomes were change from baseline resting metabolic rate adjusted for weight change ("RMR residual") and core temperature (primary); plasma triiodothyronine (T3) and tumor necrosis factor-α (secondary); and exploratory physiological and psychological measures. RESULTS: Body mass index averaged 25.1 (range: 21.9-28.0 kg/m(2)). Eighty-two percent of CR and 95% of ALparticipants completed the protocol. The CR group achieved 11.7±0.7 %CR (mean ± standard error) and maintained 10.4±0.4% weight loss. Weight change in AL was negligible. RMR residual decreased significantly more in CR than AL at 12 months (p = .04) but not 24 months (M24). Core temperature change differed little between groups. T3 decreased more in CR at M12 and M24 (p < .001), while tumor necrosis factor-α decreased significantly more only at M24 (p = .02). CR had larger decreases in cardiometabolic risk factors and in daily energy expenditure adjusted for weight change, without adverse effects on quality of life. CONCLUSIONS: Sustained CR is feasible in nonobese humans. The effects of the achieved CR on correlates of human survival and disease risk factors suggest potential benefits for aging-related outcomes that could be elucidated by further human studies. Published by Oxford University Press on behalf of the Gerontological Society of America 2015.
Authors: James Rochon; Connie W Bales; Eric Ravussin; Leanne M Redman; John O Holloszy; Susan B Racette; Susan B Roberts; Sai Krupa Das; Sergei Romashkan; Katherine M Galan; Evan C Hadley; William E Kraus Journal: J Gerontol A Biol Sci Med Sci Date: 2010-10-05 Impact factor: 6.053
Authors: Hae Young Chung; Matteo Cesari; Stephen Anton; Emanuele Marzetti; Silvia Giovannini; Arnold Young Seo; Christy Carter; Byung Pal Yu; Christiaan Leeuwenburgh Journal: Ageing Res Rev Date: 2008-07-18 Impact factor: 10.895
Authors: Amy D Rickman; Donald A Williamson; Corby K Martin; Cheryl H Gilhooly; Richard I Stein; Connie W Bales; Susan Roberts; Sai Krupa Das Journal: Contemp Clin Trials Date: 2011-07-08 Impact factor: 2.226
Authors: Reiner Jumpertz; Robert L Hanson; Maurice L Sievers; Peter H Bennett; Robert G Nelson; Jonathan Krakoff Journal: J Clin Endocrinol Metab Date: 2011-03-30 Impact factor: 5.958
Authors: Carl Pieper; Leanne Redman; Susan Racette; Susan Roberts; Manju Bhapkar; James Rochon; Corby Martin; William Kraus; Sai Das; Donald Williamson; Eric Ravussin Journal: Clin Trials Date: 2011-03-08 Impact factor: 2.486
Authors: Carmelinda Ruggiero; E Jeffrey Metter; Vojtech Melenovsky; Antonio Cherubini; Samer S Najjar; Alessandro Ble; Umberto Senin; Dan L Longo; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2008-07 Impact factor: 6.053
Authors: Li Theng Ng; Li Fang Ng; Richard Ming Yi Tang; Diogo Barardo; Barry Halliwell; Philip Keith Moore; Jan Gruber Journal: NPJ Aging Mech Dis Date: 2020-06-10
Authors: Yosuke Yamada; Joseph W Kemnitz; Richard Weindruch; Rozalyn M Anderson; Dale A Schoeller; Ricki J Colman Journal: J Gerontol A Biol Sci Med Sci Date: 2018-03-02 Impact factor: 6.053
Authors: Aseel Eid; Syed Waseem Bihaqi; Christopher Hemme; John M Gaspar; Ronald P Hart; Nasser H Zawia Journal: Epigenomics Date: 2018-05-03 Impact factor: 4.778